Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors

Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol

(2015) Tuukka Saarikoski et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

PharmGKB summary

(2014) Li Gong et al.   Pharmacogenetics and Genomics

Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Polymorphisms on Pain Sensitivity and Clinical Response to Weak Opioid Analgesics

(2013) Zalina Zahari et al.   Drug Metabolism and Pharmacokinetics

Rifampicin markedly decreases the exposure to oral and intravenous tramadol

(2012) Tuukka Saarikoski et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions

(2011) Michel Tod et al.   CLINICAL PHARMACOKINETICS

Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol’s O-demethylation via CYP2D6

(2010) Anette Green Nielsen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects

(2010) J. L. Pilgrim et al.   Forensic Science Medicine and Pathology

Antagonistic Effects of Ondansetron and Tramadol? A Randomized Placebo and Active Drug Controlled Study

(2010) Neele I. Rauers et al.   JOURNAL OF PAIN

Escitalopram Is a Weak Inhibitor of the CYP2D6-Catalyzed O-Demethylation of (+)-Tramadol but Does Not Reduce the Hypoalgesic Effect in Experimental Pain

(2009) L Noehr-Jensen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetic Drug Interactions of Synthetic Opiate Analgesics

(2009) Scott C. Armstrong et al.   PSYCHOSOMATICS